Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more.
Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications―arrhythmias, heart failure, and even death.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Dr. Imteyaz Qamar is working as an assistant professor at School of biotechnology, Gautam Buddha University, Greater Noida, India. His area on interest is Stress biology, and Cancer Genetics
He earned his Ph.D. in Molecular Endocrinology from Chonnam National University, South Korea with an emphasis on gene regulation and physiological function of an androgen receptor corepressor-19kD using mice model. He has written various manuscripts, grants, progress reports, pre-IND protocols, animal protocols and published in well reputed international journals. He has also received various awards such as Brain Korea-21 Best Research presenter award 2007, Bharath Vikas award 2016, Young Scientist Award 2017 & 2019, STE meritorious award 2019 etc. He serves as a member of editorial boards of various peer reviewed journals. He is also a member of the endocrinology society, United States of America (USA).
Dr. Pawan Kumar Maurya is a biochemist and Professor in the Department of Biochemistry at the Central University of Haryana, where he also serves as Dean of Academic Affairs. He earned his MSc and PhD in Biochemistry from the University of Allahabad. His research spans oxidative stress, aging, nanomedicine, and clinical biochemistry. He has completed postdoctoral training at several institutions in Asia and Brazil. Dr. Maurya has been honored with national and international awards for his work. He is active in professional societies including the Association of Gerontology India, the Society of Neurochemistry India, and Indian Biochemists’ and Microbiologists’ associations. His scholarly output includes books, book chapters, and numerous research articles. He contributes to technical and organizing committees for national and international conferences. A dedicated educator, he specializes in biochemical diagnostics, nanomedicine, and clinical biochemistry, with a track record of editorial work with major publishers.
Anti-cancer treatment is associated with serious cardiovascular adverse events including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications―arrhythmias, heart failure, and even death.
In view of the growing clinical and healthcare relevance of cancer survivors who are at an elevated risk of dying from cardiovascular diseases, Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyses the emerging the field of cardio-oncology; reviewing the recent advancements in the field, how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms, and concepts, which is followed by advanced state-of-art of cardio-oncology. The book starts with a brief introduction on cancer and cardiovascular diseases in cancer patients, as well as the changes observed in the cardiovascular system; which serves to provide a deeper understanding of therapeutic approaches targeting cardio-oncology. It then looks into the pathways and inhibitors involved in cancer immunology, as well as the biochemistry of tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs. The book then concludes with clinical focused chapters, including noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular risk, cardiovascular complication from cancer therapy, novel anticancer drugs related to cardiotoxicity, and principles of cardiovascular rehabilitation.
Written by leading researches in various disciplines, the book serves as a valuable resource to those who are new to the field, as well as various other specialized scientists, researchers, oncologists, cardiologists, physicians and ancillary staff.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications-arrhythmias, heart failure, and even death. 276 pp. Englisch. Bestandsnummer des Verkäufers 9780323904612
Anzahl: 2 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 44266000
Anzahl: 1 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: New. Bestandsnummer des Verkäufers 44266000-n
Anzahl: 1 verfügbar
Anbieter: Grand Eagle Retail, Bensenville, IL, USA
Paperback. Zustand: new. Paperback. Cardiovascular toxicity and therapeutic modalities targeting cardio-oncology: From basic research to advanced study Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Bestandsnummer des Verkäufers 9780323904612
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
Zustand: New. Bestandsnummer des Verkäufers 44266000-n
Anzahl: 1 verfügbar
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 44266000
Anzahl: 1 verfügbar
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irland
Zustand: New. 2022. Paperback. . . . . . Bestandsnummer des Verkäufers V9780323904612
Anzahl: 10 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications-arrhythmias, heart failure, and even death. Bestandsnummer des Verkäufers 9780323904612
Anzahl: 1 verfügbar
Anbieter: moluna, Greven, Deutschland
Kartoniert / Broschiert. Zustand: New. Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity Provides an understandi. Bestandsnummer des Verkäufers 527384236
Anzahl: 1 verfügbar
Anbieter: Russell Books, Victoria, BC, Kanada
paperback. Zustand: New. Special order direct from the distributor. Bestandsnummer des Verkäufers ING9780323904612
Anzahl: 1 verfügbar